Nearly 85% of the 1.7 million adolescents with HIV live in sub-Saharan Africa, along with half of the nearly 40 million ...
Patients who struggle to take daily HIV pills can benefit from long-acting injectable treatments, a new study has found.
Clinical Trials Arena on MSN5d
Gilead to launch Phase III once-yearly HIV PrEP trial after Phase I successGilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback